CheckMate 025

a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

P. Sharma, B. Escudier, D. F. McDermott, S. George, H. J. Hammers, S. Srinivas, S. S. Tykodi, J. A. Sosman, G. Procopio, E. R. Plimack, D. Castellano, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. C. Gauler, T. Ueda, L. A. Xu, I. M. Waxman, R. J. Motzer

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)S708
Number of pages1
JournalEuropean Journal of Cancer
Volume51
Issue numberSupplement 3
DOIs
Publication statusPublished - Sep 2015
Externally publishedYes
EventEuropean Cancer Congress - Vienna, Austria
Duration: 25 Sep 201529 Sep 2015

Cite this

Sharma, P., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., ... Motzer, R. J. (2015). CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). European Journal of Cancer, 51(Supplement 3), S708. https://doi.org/10.1016/S0959-8049(16)31926-8